The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

December 23, 2019

Michael Wang, MD, discusses the ZUMA-2 trial and the potential impact of CAR T-cell therapy on the treatment paradigm in mantle cell lymphoma.

December 14, 2019

Jennifer McQuade, MD, MS, MA, LAc, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.

December 13, 2019

Pavlos Msaouel, MD, PhD, discusses the rationale for a phase II study evaluating sitravatinib in combination with nivolumab in patients with metastatic or advanced urothelial cancer.

December 06, 2019

William G. Wierda, MD, PhD, discusses the use of chemoimmunotherapy in treating patients with chronic lymphocytic leukemia.

November 28, 2019

Tina Cascone, MD, PhD, discusses remaining challenges with perioperative immunotherapy in non–small cell lung cancer.

November 22, 2019

Neil D. Gross, MD, FACS, discusses the prognosis of patients who are diagnosed with cutaneous squamous cell carcinoma of the head and neck.

November 15, 2019

Secondary cytoreduction followed by chemotherapy was not found to improve overall survival compared with chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer.

November 14, 2019

Robert L. Coleman, MD, FACOG, FACS, discusses ongoing research efforts in cervical cancer.

November 12, 2019

Eric Jonasch, MD, discusses how to modulate the tumor microenvironment in renal cell carcinoma.

November 08, 2019

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses investigational treatment strategies in cervical cancer.

November 04, 2019

Funda Meric-Bernstam, MD, discusses the safety and efficacy of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumors.

November 03, 2019

Michael J. Keating, MBBS, has devoted much of his career to finding means of controlling chronic lymphocytic leukemia.

November 02, 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the addition of acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).

October 25, 2019

William G. Wierda, MD, PhD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

October 24, 2019

William G. Wierda, MD, PhD, discusses the evolving treatment paradigm in chronic lymphocytic leukemia and ongoing trials looking at novel approaches.

October 22, 2019

Curtis A. Pettaway, MD, discusses the need to include the genomic data of African American, Asian, and Hispanic men with prostate cancer in national registries.

October 21, 2019

William G. Wierda, MD, PhD, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia.

October 15, 2019

Robert L. Coleman, MD, FACOG, FACS, discusses what makes veliparib a unique agent in high-grade serous ovarian cancer.

October 14, 2019

William G. Wierda, MD, PhD, discusses the role of the rituximab biosimilar in the chronic lymphocytic leukemia treatment paradigm.

October 12, 2019

Neil D. Gross, MD, FACS, discusses a phase II study of neoadjuvant cemiplimab in patients with stage III/IV cutaneous squamous cell carcinoma of the head and neck.